Your shopping cart is currently empty

QX-314 bromide is a membrane-impermeable sodium channel blocker that inhibits TRPV1 and NaV1.8 expression, causing sensory-selective blockade of TRPV1 channels. It exhibits anti-inflammatory effects and may be used in studies of gastroesophageal reflux disease (GERD).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $30 | - | In Stock | |
| 50 mg | Preferential | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | - | In Stock |
| Description | QX-314 bromide is a membrane-impermeable sodium channel blocker that inhibits TRPV1 and NaV1.8 expression, causing sensory-selective blockade of TRPV1 channels. It exhibits anti-inflammatory effects and may be used in studies of gastroesophageal reflux disease (GERD). |
| In vitro | QX-314 bromide (1-60 mM) can directly activate TRPV1 channels in a concentration-dependent manner [1]. QX-314 bromide (≥30 mM) causes darkening of the oocyte membrane and induces cell death [1]. |
| In vivo | QX-314 bromide (0.2%, 10 μl, 1.6 mg/kg, plantar injection) combined with 1% lidocaine significantly prolonged the response latency to thermal and mechanical stimuli in rats [2]. QX-314 bromide (0.2%, intradermal injection) combined with 1% lidocaine completely suppressed the cutaneous trunci muscle reflex (CTMR) evoked by needle stimulation in rats, with a blockade duration of up to 6 hours [2]. QX-314 bromide (0.2%, perisciatic injection) combined with varying concentrations of lidocaine (0.5%-2%) produced dose-dependent long-lasting nociceptive blockade [2]. |
| Molecular Weight | 343.3 |
| Formula | C16H27BrN2O |
| Cas No. | 24003-58-5 |
| Smiles | [Br-].O=C(NC=1C(=CC=CC1C)C)C[N+](CC)(CC)CC |
| Relative Density. | no data available |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (116.52 mM), Sonication is recommended. H2O: 80 mg/mL (233.03 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (5.83 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO/H2O
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.